ImmVirX and BeOne Medicines Enter Clinical Collaboration to Evaluate IVX055 in Combination with tislelizumab
Phase 1 study to investigate IVX055 with tislelizumab in difficult-to-treat cancers Key Highlights ImmVirX’s receptor-targeted oncolytic virus IVX055 to be evaluated in combination with tislelizumab Phase 1 clinical trial planned to commence in second half 2026 in Australia IVX055 to become ImmVirX’s second clinical-stage asset, expanding its oncolytic immunotherapy pipeline Melbourne, Australia – 3 February […]
